Abundant studies have demonstrated that the expression of hepatic CD36 is increased during the development of NAFLD with the capability of promoting hepatic fatty acids uptake, thus resulting in the enhancement of hepatic steatosis (Steneberg et al., 2015; Zhou et al., 2020). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.